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The  successful  discovery  and subsequent  development  of  small  molecule  inhibitors  of  drug  targets  relies
on the  establishment  of robust,  cost-effective,  quantitative,  and  physiologically  relevant  in vitro  assays
that  can support  prolonged  screening  and  optimization  campaigns.  The  current  study  illustrates  the  pro-
cess of developing  and  validating  an enzymatic  assay  for the  discovery  of small  molecule  inhibitors  using
alkaline  phosphatase  from  bovine  intestine  as  model  target.  The  assay  development  workﬂow  includes
an  initial  phase  of  optimization  of  assay  materials,  reagents,  and  conditions,  continues  with  a process  of
miniaturization  and  automation,  and  concludes  with  validation  by quantitative  measurement  of  assay
performance  and  signal  variability.  The  assay  is further  evaluated  for dose–response  and  mechanism-of-creening
hosphatase
nhibitor
echanism-of-action
action  studies  required  to support  structure–activity-relationship  studies.  Emphasis  is placed  on  the most
critical  aspects  of assay  optimization  and  other  relevant  considerations,  including  the  technology,  assay
materials,  buffer  constituents,  reaction  conditions,  liquid  handling  equipment,  analytical  instrumenta-
tion,  and  quantitative  assessments.  Examples  of bottlenecks  encountered  during  assay  development  and
strategies to address  them  are  provided.
thor© 2015  The  Au
. Introduction
The discovery and development of small molecule modulators
ith desired pharmacological properties is a funneled process com-
rising multiple stages including: (i) identiﬁcation and validation of
ruggable targets for speciﬁc therapeutic areas; (ii) in vitro/in silico
creening, identiﬁcation, and characterization/proﬁling of small
olecules which potently and selectively engage the target of inter-
st, enhancing or inhibiting its molecular function; (iii) toxicology,
afety, and efﬁcacy assessments of drug candidates by in vivo pre-
linical and clinical studies. In the early stages of the drug discovery
rocess, the identiﬁcation and characterization of physiologically
elevant small molecule inhibitors markedly relies on the estab-
ishment and validation of robust, cost-effective, and scalable cell
Abbreviations: AP, alkaline phosphatase; CV, coefﬁcient of variation;
EA, diethanolamine; DiFMU, 6,8-diﬂuoro-4-methylumbelliferone; DiFMUP, 6,8-
iﬂuoro-4-methylumbelliferyl phosphate; KM, Michaelis constant; pNP, p-
itrophenol; pNPP, p-nitrophenol phosphate; SD, standard deviation; Vmax, maximal
eaction velocity; Z′ , Z prime.
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y-nc-nd/4.0/).s.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
free and cell based assays that enable to reliably and quantitatively
detect and measure variations in the activity of the target of interest
or downstream signaling molecules.
The development of such an in vitro assay for screening or pro-
ﬁling of small molecule inhibitors is driven by scientiﬁc, technical,
and budgetary considerations. Scientiﬁc considerations include the
selection and optimization of materials and conditions that mimic
the physiological condition of the target thus enabling the iden-
tiﬁcation of relevant small molecules with desired mechanisms of
action. This process may be guided in part by available literature on
the target of interest and developed further by the scientiﬁc team.
Technical considerations include, on one side, the type of tech-
nologies and equipment available to measure the desired enzyme
activity or receptor-binding afﬁnity, and, on the other side, the
throughput, assay format, reaction scale, signal window, and level
of automation that such technologies enable. Budget constraints
may  impose limitations to the type of materials, technologies, and
amount of resources invested. Eventually, the suitability of a given
assay procedure for a speciﬁc screening program must be evaluated
by quantitative methods.Failure to establish and optimize physiologically relevant assay
conditions may  lead to an excessive rate of false positives or nega-
tives and identiﬁcation of chemical entities that are inactive in vivo
or have an undesired mechanism of action. Although some general
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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uidelines on assay development [1] or target speciﬁc assay pro-
edures [2,3] can be found in literature, speciﬁc examples of
ssays developed following industry standards with systematic
escription of the procedures are limited. This study provides a
omprehensive description of the development and validation of
n enzymatic assay for small molecule screening, emphasizing the
ost critical parameters, bottlenecks, and the corrective measures
o overcome them using alkaline phosphatase from bovine intes-
ine as model target [4–6].
. Material and methods
.1. Material
The following reagents were purchased from Sigma-Aldrich:
rizma base (T1503), Hepes (H4034), MgCl2 hexahydrate (M2670),
aCl (S5886), KCl (P9333), ZnCl2 (208086), Tween 20 (F7949),
alf intestine alkaline phosphatase (P7923), sodium orthovanadate
450243), 4-nitrophenol (241326), and 4-nitrophenyl phosphate
is(tris) salt (73737).
The following reagents were purchased from Life Tech-
ologies: 6,8-diﬂuoro-4-methylumbelliferyl phosphate (D6567)
nd 6,8-diﬂuoro-4-methylumbelliferone (6,8-diﬂuoro-7-hydroxy-
-methylcoumarin) (D6566).
For the colorimetric assay, 96-well clear non-treated plates were
urchased from Cayman Chemical (400014), and 384-well clear
on-binding surface plates were purchased from Corning (3640).
or the ﬂuorometric assay, 384-well black non-binding standard
lates were purchased from Greiner (781900), and 384-well black
on-binding low volume plates were purchased from Corning
3676).
Polypropylene reservoirs (Socorex 330.01) and polypropylene
6-well plates (Corning 3363) were used as source container for
resh working solutions prior to their transfer to the assay plate
sing multichannel pipettes (Gilson and Finntip). Polypropylene
84-well plates (Corning 3657) were used as source container for
utomated transfers using Hummingbird Plus liquid handler (Dig-
lab). Polypropylene 50 mL  Falcon tubes (BD Biosciences 352070)
ere used as source container for automated transfers using Mul-
idrop Combi dispenser (Thermo Scientiﬁc).
.2. Reagents
The alkaline phosphatase (AP) stock was stored at 4 ◦C. AP inter-
ediate dilutions were prepared in 1× assay buffer containing 50%
lycerol and stored at 4 ◦C. Working solutions of p-nitrophenol
hosphate (pNPP), 6,8-diﬂuoro-4-methylumbelliferyl phosphate
DiFMUP), Na3VO4, and AP were prepared fresh in assay buffer or
2O as described in the next section and added to reservoirs or 96-
ell polypropylene plates prior to transfer to the assay plate using
ultichannel pipettes.
.3. Alkaline phosphatase assay
.3.1. Colorimetric assay
Assay buffer containing TRIS was prepared at 2× ﬁnal concen-
ration and stored at room temperature. pNPP stock solution was
repared at 100 mM in dH2O and stored at −20 ◦C. p-Nitrophenol
pNP) stock solution was prepared at 50 mM in dH2O and stored at
20 ◦C.
The ﬁnal reaction conditions were 50 mM Tris–HCl pH 7.5,
35 mM NaCl, 7.5 mM KCl, 5 mM MgCl2, 0.1 mM ZnCl2, 0.3 mM
ween 20 or as speciﬁed in the text. pNPP and AP concentrations
aried as speciﬁed in the text. AP was prepared at 2× ﬁnal concen-
ration in 2× assay buffer, whereas pNPP was prepared at 2× ﬁnal
oncentration in dH2O. Reactions were initiated by adding equaln and Quantiﬁcation 4 (2015) 1–9
volumes of AP and pNPP to the assay plate (50 L each to 96-well
non-treated plates or 25 L each to 384-well non-binding plates)
using a manual multichannel pipette. Plates were spun down and
A425 was  monitored continuously at room temperature with an
Analyst GT microplate reader (Molecular Devices).
2.3.2. Fluorometric assay
Assay buffer containing HEPES was  prepared at 1× ﬁnal
concentration and stored at 4 ◦C. DiFMUP and 6,8-diﬂuoro-4-
methylumbelliferone (DiFMU) stock solutions were prepared at
10 mM in DMSO and stored at −20 ◦C. Na3VO4 stock solution was
prepared at 50 mM in H2O and stored at −20 ◦C.
The ﬁnal reaction conditions were 50 mM HEPES pH 6.5, 135 mM
NaCl, 7.5 mM KCl, 5 mM MgCl2, 0.1 mM ZnCl2, 0.3 mM Tween 20 or
as speciﬁed in the text. DiFMUP and AP concentrations varied as
speciﬁed in the text. For reactions without inhibitor in standard
volume plates, AP was prepared at 2× ﬁnal concentration in 1×
assay buffer, and DiFMUP was  prepared at 2× ﬁnal concentration
in 1× assay buffer. Reactions were initiated by adding 25 L of 2×
AP and 25 L of 2× DiFMUP to the assay plate using a manual mul-
tichannel pipette. For reactions with Na3VO4 in standard volume
plates, AP was prepared at 2.5× ﬁnal concentration in 1× assay
buffer, DiFMUP was  prepared at 2× ﬁnal concentration in 1× assay
buffer, and Na3VO4 was prepared at 10× ﬁnal concentration in H2O.
Reactions were initiated by adding 20 L of 2.5× AP, 5 L of 10×
Na3VO4, and 25 L of 2× DiFMUP to the assay plate using a manual
multichannel pipette. For reactions with Na3VO4 in low volume
plates, AP or a mixture of AP and Na3VO4 were prepared at 3×
ﬁnal concentration in 1× assay buffer, and DiFMUP  was prepared
at 1.5× ﬁnal concentration in 1× assay buffer. Reactions were ini-
tiated by adding 5 L of 3× AP or AP plus Na3VO4, and 10 L of
1.5× DiFMUP to the assay plate using a Multidrop Combi dispenser
(Thermo Scientiﬁc). Plates were spun down and incubated at 37 ◦C.
Fluorescence intensity (ex: 358 nm,  em:  455 nm)  was monitored
continuously at 37 ◦C or at a single end-point as indicated in the
text and ﬁgure legends with a PHERAstar microplate reader (BMG
Labtech).
The concentration of enzyme in each reaction was calculated
according to the nominal concentration of the original stock pro-
vided by the manufacturer (2000 DEA Units in 15 L) and expressed
as DEA Units L−1. For the validation tests, 0.1 L of DMSO was
transferred to the low volume plates prior to dispensing of the other
reagents using Hummingbird Plus liquid handler (Digilab).
For both colorimetric and ﬂuorometric assays, blank reactions
contained the same constituents as the test reactions except AP.
2.4. Data analysis
Initial reaction velocities were estimated by converting blank
subtracted Absorbance or Fluorescence units from the reaction
progress curves into product concentration units using pNP or
DiFMU calibration curves, respectively, and calculating the slope
of the normalized curves in the initial linearity phase following the
equation:
v0 =
P
t
(1)
where v0 is the initial reaction velocity (nmols min−1), P  is the
increment in amount of product produced in the linear phase
(nmols), and t  is the time window of the linear phase (min).Enzyme kinetic parameters were calculated by plotting ini-
tial reaction velocities against substrate concentration and ﬁtting
the data points by non-linear regression to the classical Michaelis
Menten steady state model (2) or a variant of the model that
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ccounts for positive and negative cooperativity to the substrate
inding site (3):
0 =
Vmax × S
S + KM
(2)
0 =
Vmax × Sn
Sn + KnM
(3)
here v0 is the initial reaction velocity (nmols min−1), S is the con-
entration of substrate (M),  Vmax is the maximal reaction velocity
nmols min−1), KM is the Michaelis constant (M),  and n is the Hill
oefﬁcient that quantiﬁes the level of cooperativity.
The Vmax units retrieved from the regression analy-
is (nmols min−1) were converted into standard Vmax units
mols min−1 mg−1) by normalizing to the mass of protein (mg) in
he reaction. The mass of protein per reaction was estimated from
he nominal speciﬁc activity (≥4000 DEA Units mg−1) and concen-
ration (2000 DEA Units in 15 L) provided by the manufacturer
nd the corresponding dilution factor.
The catalytic constant or turnover number (kcat) was calculated
ssuming a molecular mass of 70 kDa per subunit of enzyme [5].
Percent enzyme inhibition was calculated by normalizing raw
uorescence intensity signal at 60 min  in the presence of inhibitor
o the maximum signal in the absence of inhibitor following the
quation:
 inhibition = 100 ×
(
1 − RFUI
RFUC
)
(4)
here % inhibition is the percent of enzyme inhibition, RFUI is the
ignal intensity at 60 min  in the presence of inhibitor, and RFUC is
he signal intensity at 60 min  in the absence of inhibitor.
Half maximal inhibitory concentrations (IC50s) were estimated
y plotting percent inhibition as a function of inhibitor concentra-
ion and ﬁtting the corresponding concentration–response curves
o the following four parameter logistic model:
 inhibition = A + B − A
1 + ((C/X )ˆD) (5)
here % inhibition is the percent of enzyme inhibition, A and B are
he minimum and maximum projected percent inhibition of the
urve (bottom and top asymptotes), respectively, C is the relative
C50, and D is the Hill coefﬁcient.
The Z prime (Z′) was calculated according to the following equa-
ion:
′ = 1 − 3 × max − min
max − min
(6)
here max and min are the standard deviations of the maximum
nd minimum signals, respectively, and max and min are the
eans of the maximum and minimum signals, respectively.
The coefﬁcient of variation (CV) was calculated according to the
ollowing equation:
V = 

(7)
here  and  are the standard deviation and the mean of a pop-
lation of values, respectively.
Regression analyses were done using either XLﬁt (iDBS) or
raphPad Prism (GraphPad Software).
. Results
.1. Assay development.1.1. Assay development workﬂow and selection of initial assay
onditions
Supplemental Fig. 1 summarizes the assay development and
ptimization workﬂow followed in this study. AP from calf intestinen and Quantiﬁcation 4 (2015) 1–9 3
was selected as model target to illustrate the assay development,
validation and optimization process. The initial substrate cho-
sen for determination of AP activity was  p-nitrophenol phosphate
(pNPP) which dephosphorylates into p-nitrophenol (pNP), a sol-
uble chromophore with a maximum molar extinction coefﬁcient
at 405 nm under alkaline conditions [7]. pNPP is a low cost sub-
strate, commonly available from most vendors. Furthermore, this
homogeneous technology enables continuous determination of
phosphatase activity in real time. During the initial stages of assay
development, buffer composition and assay conditions were deter-
mined from the literature (50 mM Tris–HCl pH 8.6, 5 mM MgCl2,
2 mM pNPP) and subsequently optimized. Reactions were initiated
by mixing equal volumes (25 L in 384-well plates or 50 L in 96-
well plates, respectively) of AP in 2× assay buffer and 4 mM pNPP in
dH2O. Blank reactions contained the same constituents as the test
reactions except AP. The readout of the colorimetric reaction was
conducted at room temperature using the Analyst GT microplate
reader (Molecular Devices) equipped with a 425/35 nm bandpass
ﬁlter.
3.1.2. Selection of assay plates
One critical aspect to consider at the initial stages of assay
development is the selection of a plate surface with the ade-
quate protein binding capacity. Fig. 1A and B illustrates the effect
of the surface binding capacity on AP activity. When a range
of enzyme concentrations were assayed in non-binding surface
(NBS) plates, the reaction progress curves converged to a com-
mon equilibrium value. In contrast, in non-treated (NT) plates
the curves diverged, an evidence of enzyme inactivation over the
reaction course. The effect of the binding capacity on enzyme sta-
bility was veriﬁed by pre-incubating the enzyme in NT and NBS
plates and initiating the reactions by substrate addition at differ-
ent pre-incubation times (Fig. 1C–F). As anticipated, initial reaction
velocities decayed upon pre-incubation of the enzyme in NT but
not in NBS plates, conﬁrming the instability of AP in NT plates.
Therefore NBS plates were selected for further optimization of this
assay.
3.1.3. Optimization of assay buffer
A second important aspect that must guide the development
of an in vitro assay is the cellular and physiological conditions
of the target in vivo (cofactors, salt concentration, pH, and asso-
ciation with lipids or membranes). Despite the animal origin of
the target under investigation, the assay buffer composition was
altered to mimic  more closely the native conditions of the human
intestine for illustrative purposes. Sodium and potassium concen-
trations in the small intestine range from 130 to 140 mM and from
5 to 10 mM,  respectively, whereas the pH range varies from 6.6 to
7.5 [8]. Besides, AP is a homodimeric enzyme with each subunit
containing two  Zn2+ and one Mg2+ ions in the catalytic site [6].
Based on these considerations, the buffer composition was  mod-
iﬁed to 50 mM Tris–HCl, 135 mM NaCl, 7.5 mM KCl, 5 mM MgCl2,
0.1 mM ZnCl2. The pH was preliminary set to 7.5 and subsequently
optimized.
Regarding the cellular environment, intestinal AP is anchored
to the outer leaﬂet of the plasma membrane by a glycosyl-
phosphatidylinositol moiety [6]. Therefore, the effect of
membrane-mimicking agents on AP activity was tested. Sup-
plemental Fig. 2 illustrates the effect of one zwitterionic (CHAPS)
and two non-ionic (Triton X-100 and Tween 20) detergents at two
concentrations above their critical micelle concentration (cmc) on
the activity of AP. The three detergents increased AP activity by
up to 40% irrespective of the concentration tested. Therefore, the
assay buffer was  supplemented with 0.3 mM Tween 20.
4 V. Sancenon et al. / Biomolecular Detection and Quantiﬁcation 4 (2015) 1–9
Fig. 1. Effect of protein binding capacity of assay plate on AP stability. Reaction progress curves of the AP colorimetric assay at the indicated concentrations of enzyme
(DEA  U/L) in non-treated (A and C) and non-binding surface (B and D) plates. Reactions were initiated by addition of substrate before (A and B) or after (C and D) pre-
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would be 8 M pNPP. However, 8 M pNP fell below the detection
limits of the available equipment due to the low extinction coefﬁ-
cient of pNP at neutral pH, precluding further advancement of the
development process using the current conditions.
Fig. 2. Determination of optimal pH and substrate concentration for the hydrolysis
of  pNPP by AP at room temperature. (A) Variation of initial reaction velocity as a func-ncubation of the enzyme in the assay plate. Initial reaction velocities as a function
rom  panels C and D.
.1.4. Iterative optimization of substrate type and concentration,
H, and measurement technology
The third critical constituent of the assay reaction mix  that
equires ﬁne tuning is the concentration of substrate. Typically, the
nzymatic screening assays to identify small molecule inhibitors
re conducted at a concentration of substrate near the KM to ensure
n even representation of small molecule hit compounds with dif-
erent inhibition modalities. The pH optima for some enzymes,
ncluding AP, in turn varies with substrate concentration [9]. There-
ore, if information on the physiological pH is not available, both pH
nd substrate concentration must be optimized simultaneously.
A precise determination of KM requires the calculation of initial
eaction velocities at a range of substrate concentrations spanning
he KM. Before performing this experiment, the lowest testable con-
entration of substrate enabled by the available technology needs
o be established. Calibration curves of the substrate or product
rovide an indication of the system detection limit. For the AP col-
rimetric assay, 16 M pNPP was estimated as the lowest testable
oncentration of substrate (data not shown). Subsequently, enzyme
oncentration was adjusted to the lowest substrate concentration
n a titration experiment (Supplemental Fig. 3). An appropriate
nzyme concentration must generate sufﬁcient data points in the
inear range to enable accurate estimation of initial reaction veloc-
ties. Based on these considerations, AP concentration was  set
o 5 DEA U/L  for pNPP concentrations equal to or higher than
6 M.
To determine the kinetic parameters of AP at different pH values,
eaction progress curves were obtained at a range of substrate con-
entrations for each pH (Supplemental Fig. 4A–D). The estimated
nitial velocities were plot against substrate concentration and ﬁte-incubation time in non-treated (E) and non-binding surface (F) plates estimated
by non-linear regression analysis to the Michaelis Menten model
(Fig. 2A). The corresponding Vmax, kcat, and KM estimated from the
analysis are shown in Table 1. Moreover, the estimated catalytic
efﬁciency (kcat/KM) of AP for pNPP was maximal at pH 7.5 (Table 1).
Likewise, a re-plot of initial velocity versus pH at different substrate
concentrations illustrates the shift in pH optima from alkaline at
10 mM pNPP to neutral at 16 M pNPP as previously reported [9]
(Fig. 2B). Therefore, these studies indicated that the optimal sub-
strate concentration for small molecule inhibitor screen at pH 7.5tion of pNPP concentration at pH 6.5–10.0. Plots were ﬁt by non-linear regression
analysis to the Michaelis-Menten model as described in the text. (B) Dependence of
AP  pH optima on pNPP concentration. Initial reaction velocities from panel A were
re-plot as a function of pH for each substrate concentration tested to show the shift
in  optimal pH toward neutrality at low pNPP concentrations.
V. Sancenon et al. / Biomolecular Detection and Quantiﬁcation 4 (2015) 1–9 5
Table  1
Kinetic parameters for the hydrolysis of pNPP by AP at room temperature and different pHs.
pH Vmax (mol  min−1 mg−1)* kcat (s−1) KM (M)* kcat/KM (M−1 s−1) Hill coefﬁcient
6.5 20 ± 2 23 2 ± 8 1.44 × 107 1
7.0 58  ± 7 68 4 ± 12 1.84 × 107 1
7.5  132 ± 5 154 8 ± 3 1.86 × 107 1
8.0  246 ± 12 287 18 ± 5 1.60 × 107 1
8.5  392 ± 14 458 37 ± 7 1.24 × 107 1
9.0  463 ± 42 540 206 ± 82 0.26 × 107 0.68
385 ± 250 0.16 × 107 0.76
330 ± 74 0.22 × 107 1
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Fig. 3. Determination of optimal pH and substrate concentration for the hydrolysis
of  DiFMUP by AP at 37 ◦C. (A and B) Variation of initial reaction velocity as a function
of  DiFMUP concentration at pH 6.5–8.0 (A) and pH 6.5–7.0 (B). Plots were ﬁt by
non-linear regression analysis to the Michaelis-Menten model as described in the
T
K9.5  515 ± 86 601 
10.0  626 ± 40 731 
* 95% conﬁdence intervals are indicated for Vmax and KM.
Two alternative strategies were considered to increase assay
ensitivity using the available equipment: (i) alkalinization of the
eaction with NaOH at the assay end-point and prior to the readout;
ii) or use of an alternative technology which provided increased
ignal at neutral pH values. The ﬁrst option required minor changes
o the assay protocol but was less likely to produce a signal incre-
ent of the magnitude required to meet subsequent validation
ests. In contrast, the second option required major changes to
ssay materials, analytical instrumentation, and conditions but
as more likely to produce the desired response. Consequently,
NPP was replaced by 6,8-diﬂuoro-4-methylumbelliferyl phos-
hate (DiFMUP), a ﬂuorogenic substrate that, upon hydrolysis,
enerates 6,8-diﬂuoro-4-methylumbelliferone (DiFMU), a ﬂuo-
ophore with excitation and emission maxima at 358 and 450 nm,
espectively, that enables continuous determination of phos-
hatase activity at acidic, neutral, and alkaline pH values [10].
The other factor that can have a signiﬁcant impact on assay per-
ormance and validation tests is the instrument used for particular
ssay readout. Therefore, if multiple microplate readers equipped
ith appropriate optics to support the technology of interest are
vailable, the selection must be driven by instrument performance.
or the ﬂuorometric assay, PHERAstar (BMG Labtech) and EnVi-
ion (Perkin Elmer) were evaluated to quantify DiFMU. To choose
etween them, the settings (light intensity, gain, and focal height)
f both readers were optimized with DiFMU and DiFMUP standard
olutions and their signal-to-background ratio at the optimized
ettings were compared (Supplemental Fig. 5). PHERAstar was
elected for further assay development due to its higher sensitivity.
The kinetic parameters and optimal pH of an enzyme vary with
he substrate class. Therefore, optimal pH and substrate concen-
ration for DiFMUP were determined as described for pNPP (Fig. 3).
s the optimal pH was expected to fall within 6.5–7.5, TRIS was
eplaced by HEPES, which has a more effective buffering capacity
t physiological pH [6.8–8.2]. All other assay buffer components
ere kept unchanged. Further, the assay temperature was  shifted
o 37 ◦C to mimic  more closely the physiological conditions of the
arget. Table 2 displays the estimated kinetic parameters for the
ydrolysis of DiFMUP by AP at 37 ◦C from pH 6.5–8. At 95% conﬁ-
ence interval, the estimated Vmax and KM in the ﬂuorometric assay
as tighter than in the colorimetric assay, indicating higher robust-
ess and sensitivity of the ﬂuorescence-based technology. As with
NPP, the catalytic constant (kcat) of AP against DiFMUP increases
hereas the substrate afﬁnity (reciprocal of KM) decreases with
ncreasing pH, resulting in a maximum catalytic efﬁciency (kcat/KM)
able 2
inetic parameters for the hydrolysis of DiFMUP by AP at 37 ◦C and different pHs.
pH Vmax (mol  min−1 mg−1)* kcat (s−1) 
6.5 32 ± 2 37 
7.0 71  ± 3 82 
7.5  126 ± 3 147 
8.0  181 ± 1 211 
* 95% conﬁdence intervals are indicated for Vmax and KM.text.  Due to the decrease in KM at lower pH values, curves at pH 6.5 and 7.0 were
re-evaluated using lower DiFMUP concentrations to accurately calculate the KM at
those pH values (B).
at pH 6.5. Based on these results, DiFMUP concentration was set to
0.2 M and pH to 6.5 for screening of inhibitors.
3.1.5. Optimization of enzyme concentration
Enzyme concentration is the last component of the assay reac-
tion mix  that requires ﬁne adjustment upon establishing substrate
concentration. Ideally, the amount of enzyme in the assay reaction
has to be sufﬁciently low to ensure: (i) reaction linearity within a
time interval adequately long to accommodate the intended plate
throughput; (ii) less than 10–15% substrate depletion at the assay
end-point to ensure steady state conditions throughout the assay
course; (iii) and enzyme concentration signiﬁcantly lower than the
expected Ki or Ki ′ of the inhibitors. However, the ﬁnal enzyme con-
centration in the reaction has to be sufﬁciently high to provide
acceptable signal window.
AP concentration was  optimized for the pre-set assay conditions
in a titration experiment. Supplemental Fig. 6 displays the reaction
progress curves for the hydrolysis of DiFMUP by AP obtained at a
range of enzyme concentrations. As the reading time per plate in
the preset PHERAstar settings was  2.5 min, a hypothetical screen
with an intended throughput of 20 plates per run would require
sustained reaction linearity for at least 50 min  after the readout of
the ﬁrst assay plate and no more than 10–15% of substrate depletion
upon reading of the last plate. Based on these considerations, ﬁnal
AP concentration was  set to 0.0781 DEA U/L  since it is the high-
est enzyme concentration that satisﬁed these criteria with at least
KM (M)* kcat/KM (M−1 s−1) Hill coefﬁcient
0.20 ± 0.04 1.96 × 108 1
0.50 ± 0.04 1.65 × 108 1
1.4 ± 0.2 1.03 × 108 1
2.8 ± 0.1 0.77 × 108 1
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Fig. 4. Mechanism of action studies using Na3VO4. (A) Concentration-dependent inhibition of AP by Na3VO4 at pH 6.5, 37 ◦C, and 0.2 M DiFMUP. Fluorescence intensity
was  recorded at 60 min of reaction and percent inhibition was  calculated and plot as a function of Na3VO4 concentration. Plots were ﬁt by non-linear regression analysis
to  a four parameter logistic model as described in the text to determine the IC50. (B) Reversibility test. Enzyme was  co-incubated in the presence or absence of Na3VO4
for 30 min  and rapidly diluted with substrate as described in the text. The corresponding reaction progress curves were recorded. (C) Effect of DiFMUP concentration on
Na3VO4 IC50. Concentration–response curves at a range of DiFMUP concentrations [0.025–1.6 M]  were obtained and plot as in A. (D) Variation of Na3VO4 IC50 as a function
o iFMU
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and Table 4), conﬁrming the competitive nature of the AP inhibi-f  DiFMUP concentration. (E) Variation of initial reaction velocity as a function of D
t  by non-linear regression analysis to the Michaelis-Menten model as described in
hows the intersection of the lines in the Y axis, and indication of a competitive me
0 min  of reaction time. Higher AP concentrations would shorten
he linearity interval whereas lower concentrations would com-
romise signal window.
.1.6. Determination of DMSO tolerance
Since small molecule library compounds are typically dissolved
n DMSO, it is crucial to determine the DMSO tolerance of the in vitro
ssay, that is, the minimum concentration of DMSO that reduces
nzyme activity signiﬁcantly (>10%). Supplemental Fig. 7 shows
hat DMSO concentrations up to 1.5% caused less than 10% decrease
n reaction velocity. This observation implies that library compound
tocks should be prepared at concentrations that permit screening
t or below 1.5% DMSO in the ﬁnal reaction volume.
.2. Assay validation using known small molecule inhibitors of AP
.2.1. Reversibility studies
To verify the suitability of the optimized assay conditions for
ompound screening and mechanism of action studies, a standard
ompetitive inhibitor of AP, sodium orthovanadate (Na3VO4), was
sed. Initially, concentration–response assays were run to deter-
ine the half maximal inhibitory concentration (IC50) of Na3VO4
t 0.2 M DiFMUP (Fig. 4A). Subsequently, the reversibility of the
nzyme-inhibitor complex was evaluated by pre-incubating AP at
00-fold the ﬁnal assay concentration with Na3VO4 at 10-fold the
C50 for 30 min  and subsequently diluting the mixture 100-fold
ith substrate to a ﬁnal enzyme concentration of 1× and inhibitorP concentration at a range of Na3VO4 concentrations [0.084–61.7 M].  Plots were
ext. (F) Lineweaver–Burk or double reciprocal plot of the data displayed in panel E
m of inhibition.
concentration of 0.1× IC50. The expected reaction progress curves
should be curvilinear if the inhibition is slowly reversible, lin-
ear with 91% recovery of enzymatic activity if the inhibition is
rapidly reversible or linear with 9% recovery if the inhibition is
irreversible [11]. The reaction progress curve obtained for AP after
rapid dilution of Na3VO4 was  linear with 73% fractional activity
(Fig. 4B), indicating that Na3VO4 is a rapidly reversible inhibitor of
AP.
3.2.2. Mechanism of action studies
To elucidate the inhibition modality of reversible inhibitors, ini-
tial reaction velocities must be determined in the presence of a
range of substrate concentrations spanning the KM and inhibitor
concentrations spanning the estimated IC50. This type of study
enables to inspect the variation of IC50 with substrate concen-
tration, and the variation of the enzyme kinetic parameters with
inhibitor concentration, the two diagnostic tests for mechanism-
of-action assessment. Fig. 4C and D, and Table 3 show the increase
in the estimated IC50 of Na3VO4 with increasing DiFMUP con-
centrations, a ﬁrst indication of a competitive mode of action.
Consistently, the apparent KM but not the Vmax of the reaction
increases with increasing substrate concentrations (Fig. 4E and F,tion by Na3VO4. These validation tests veriﬁed the suitability of the
selected assay conditions for subsequent inhibitory screening, IC50
determination, and mechanism-of-action studies, and concluded
the assay optimization phase.
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Table  3
Effect of DiFMUP concentration on Na3VO4 IC50.
DiFMUP (M) 0.025 0.050 0.100 0.200 0.400 0.800 1.600
IC50 (M)* 1.0 ± 0.4 1.5 ± 0.4 1.6 ± 0.3 2.3 ± 0.4 4.0 ± 0.4 6.1 ± 0.9 11 ± 3
* 95% conﬁdence intervals are indicated for IC50.
Table 4
Effect of Na3VO4 concentration on apparent AP kinetic parameters.
Na3VO4 (M) 0.000 0.084 0.250 0.760 2.28 6.68
V (RFU min−1)* 550 ± 18 567 ± 18 561 ± 35 566 ± 24 546 ± 32 513 ± 53
0.19 
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KM (M)* 0.13 ± 0.02 0.17 ± 0.02 
* 95% conﬁdence intervals are indicated for Vmax and KM.
.3. Assay miniaturization and automation
The purpose of assay miniaturization is to minimize the con-
umption of reagents (and therefore reduce cost) and increase
he assay throughput without compromising the signal window
r assay performance. This process may  involve changes in assay
ormat, reaction scale, and microplate reader settings without mod-
ﬁcations to assay conditions. The purpose of automation is to
tandardize operations for higher throughput and day-to-day con-
istency. This process also involves changes in the handling of the
ssay reagents. Eventually, the impact of implementing changes in
he assay format and operations on performance and signal stability
ust be evaluated.
The AP assay was transferred from standard to low volume
lates and scaled down from 50 L to 20, 15, and 10 L reaction vol-
me. Reader settings (gain and focal height) were re-optimized for
he new assay format using a standard solution of DiFMU. Automa-
ion was implemented with a Hummingbird Plus liquid handler
Digilab) for the addition of DMSO or compounds and a Multidrop
ombi dispenser (Thermo Scientiﬁc) equipped with standard and
mall tubing cassettes for the addition of assay buffer, enzyme, and
ubstrate. The impact of these changes on assay performance and
ignal variability was evaluated by testing the different conditions
n a full plate format, each one including 192 wells for maximum
enzyme and substrate) and minimum (assay buffer and substrate)
ignal controls. Fluorescence was recorded at 30, 45, 60, and 75 min
o track assay performance throughout the assay course, and Z
rime (Z′) and coefﬁcient of variation (CV) of the maximum sig-
al at each combination of miniaturized volume, tubing cassette,
nd assay end-point were computed (Supplemental Fig. 8). The Z′ is
 statistical parameter that measures the suitability of an assay for
ompound screening based on the signal window and the disper-
ion of the maximum and minimum signals. The CV is a statistical
arameter that measures the dispersion or variability of a popu-
ation of values based on the ratio of the standard deviation to
he mean. Among all conditions tested, the maximum assay per-
ormance was obtained in 15 L reactions using the small tubing
assette for dispensing of reagents (Supplemental Fig. 8).
ig. 5. Assessment of spatial uniformity for the AP ﬂuorometric assay. Spatial variability o
nd  row (B) for the plate uniformity study described in the text. The scatter plots corresp
oint  (60 min) out of the total of four time points recorded for each plate and day.± 0.04 0.31 ± 0.04 0.57 ± 0.09 1.3 ± 0.3
3.4. Final assessment of assay performance for small molecule
screening
The suitability of the optimized assay conditions, format, and
operations for small molecule screening and proﬁling needs to
be evaluated by quantitative methods. Guidelines for formal
assay validation procedures, analyses, and acceptance criteria are
available in the Assay Guidance Manual by Eli Lilly and Company
and the National Center for Advancing Translational Sciences:
http://assay.nih.gov/assay/index.php/Section2:Plate Uniformity
and Signal Variability Assessment. Typically, it is recommended to
conduct an assessment of spatial uniformity and signal variability
within plates and between plates and days by running a limited
number of assay plates in independent days. The plates must
include a signiﬁcant number of replicate wells for the theoretical
maximum (MAX; enzyme and substrate), medium (MID; enzyme,
inhibitor, and substrate) and minimum (MIN; assay buffer and
substrate) signals. This test provides a quantitative estimation of
the assay robustness and stability.
In general, an assay is considered acceptable for small molecule
screening if the assay parameters meet the following criteria:
1. Spatial uniformity. Signal variability due to material drift or edge
effects must not exceed 20%.
2. Intra-plate variability. For all plates and days, the CV of each signal
must be lower than 20%, the SD of the normalized medium signal
(in percent inhibition) lower than 20%, and the Z′ higher than 0.4.
3. Inter-plate and inter-day variability. The difference in the normal-
ized medium signal (in percent inhibition) between plates and
days must be lower than 15%.
The assessment of assay performance of AP assay comprised
three runs of three full assay plates, each one including 128 wells
for MAX, MID, and MIN  signals spread across the plate in an inter-
leaved format. Fluorescence was  read at 30, 45, 60, and 75 min as
end-points. Scatter plots of the maximum, medium, and minimum
signals against well coordinates by rows and by columns for each
f the maximum (MAX), medium (MID), and minimum (MIN) signals by column (A)
ond to one representative plate out of the total of nine plates tested and one time
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Table  5
Intra-plate signal variability of the AP ﬂuorometric assay.
Parameter Z’ CV (MAX) CV (MIN) CV (MID) SD of MID  (%)
Time (min) 30 45 60 75 30 45 60 75 30 45 60 75 30 45 60 75 30 45 60 75
Plate 1. Day 1 0.63 0.74 0.79 0.67 6.5 5.4 4.6 8.5 9.4 8.5 8.2 7.7 4.1 3.6 3.4 3.3 3.3 2.5 2.2 2.0
Plate  1. Day 2 0.79 0.83 0.84 0.74 2.1 2.2 2.3 5.9 10.8 11.1 12.3 11.6 2.7 2.7 3.1 3.1 2.2 1.9 2.0 1.9
Plate  1. Day 3 0.63 0.74 0.81 0.84 8.3 5.9 4.8 4.3 2.7 5.3 2.7 2.9 2.8 2.6 2.6 2.6 2.2 1.8 1.7 1.6
Plate  2. Day 1 0.80 0.84 0.86 0.87 2.5 2.6 2.7 2.7 9.1 8.0 7.8 8.3 2.2 2.3 2.5 2.6 1.7 1.6 1.6 1.6
Plate  2. Day 2 0.84 0.87 0.89 0.90 2.6 2.4 2.3 2.4 5.3 5.2 4.7 4.5 2.2 2.4 2.4 2.4 1.8 1.7 1.6 1.5
Plate  2. Day 3 0.88 0.90 0.90 0.90 2.1 2.2 2.4 2.5 3.4 2.8 2.8 3.0 12.2 9.6 8.0 7.1 10.0 6.8 5.2 4.4
Plate  3. Day 1 0.77 0.83 0.83 0.85 3.2 2.8 3.2 3.1 9.1 9.0 9.0 8.7 11.0 8.8 7.2 6.3 9.0 6.2 4.7 3.9
Plate  3. Day 2 0.84 0.88 0.81 0.83 2.4 2.1 2.1 2.2 5.9 6.2 19.7 18.5 5.8 9.7 7.6 6.2 4.8 6.9 5.0 3.9
Plate  3. Day 3 0.76 0.81 0.84 0.85 2.5 2.5 2.6 2.8 12.8 12.2 12.1 11.5 2.1 2.1 2.4 2.5 1.7 1.5 1.6 1.6
Acceptance criteria >0.5 ≤20%
Table 6
Inter-plate and inter-day signal variability of the AP ﬂuorometric assay.
aDifference in MID  signal
between plates (%)
Day 1 Day 2 Day 3
Plate 1 Plate 2 Plate 3 Plate 1 Plate 2 Plate 3 Plate 1 Plate 2 Plate 3
30 min Day 1 Plate 1 – 1.8 0.4 2.3 0.3 3.7 4.3 4.4 3.1
45 min
Plate 2 1.3 – 1.4 0.4 2.1 1.8 2.4 2.5 1.3
Plate  3 0.5 1.8 – 1.8 0.7 3.3 3.9 4.0 2.7
Day  2 Plate 1 2.0 0.7 2.5 – 2.5 1.4 2.0 2.1 0.8
Plate  2 3.0 4.3 2.5 5.0 – 3.9 4.5 4.6 3.3
Plate  3 3.9 2.6 4.4 1.9 6.9 – 0.6 0.7 0.6
Day  3 Plate 1 5.1 3.8 5.6 3.1 8.0 1.2 – 0.1 1.2
Plate  2 3.3 2.0 3.8 1.3 6.3 0.6 1.8 – 1.3
Plate  3 2.9 1.6 3.4 0.9 5.9 1.0 2.1 0.3 –
60  min Day 1 Plate 1 – 1.0 0.3 1.1 0.1 6.0 1.7 2.6 2.0
75 min
Plate 2 2.7 – 0.7 0.1 0.9 5.0 0.7 1.6 1.0
Plate  3 0.5 2.3 – 0.8 0.1 5.7 1.4 2.3 1.7
Day  2 Plate 1 1.4 1.4 0.9 – 0.9 4.9 0.6 1.5 0.9
Plate  2 0.1 2.6 0.4 1.3 – 5.9 1.6 2.5 1.9
Plate  3 7.3 4.6 6.9 6.0 7.2 – 4.3 3.4 4.0
Day  3 Plate 1 2.3 0.4 1.8 0.9 2.2 5.0 – 0.9 0.3
Plate  2 3.2 0.5 2.7 1.8 3.1 4.1 0.9 – 0.6
Plate  3 2.3 0.4 1.9 1.0 2.2 5.0 0.0 0.9 –
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a Difference in normalized medium signals (% inhibition) between the indicated 
late, day, and time point revealed no signiﬁcant positional effects
Fig. 5).
Likewise, intra-plate, inter-plate, and inter-day signal variability
arameters for each plate, day, and time point met  assay accep-
ance criteria excluding no more than three data points per plate
Tables 5 and 6). This ﬁnal assessment of assay performance con-
rmed the suitability of the developed assay for screening of small
olecule inhibitors.
. Discussion
The development of physiologically relevant and statistically
obust in vitro assays is a crucial step in the early drug discovery pro-
ess. Multiple factors contribute to the successful optimization of
n assay, including the selection of the adequate assay technology
nd materials, buffer composition, reaction conditions, enzyme and
ubstrate concentrations, liquid handling equipment, and analyti-
al instrumentation. Screening paradigms with well validated assay
ystems help in identifying and optimizing clinically relevant leads.
he goal of the present study was to provide a complete overview
n the critical processes required to successfully develop and vali-
ate a cell-free enzymatic assay for small molecule screening and
roﬁling using calf intestine AP as model target.
Initially, the optimal plate type was selected to ensure enzyme
tability. Inadequate protein binding to the assay plate may  lead
o premature loss of enzyme activity during the assay course,<15%
.
shortening of screening window and, most importantly, leading
to inaccurate estimations of enzyme activity. In this regard, non-
binding plates were shown to sustain AP activity for at least 4 h.
Likewise, buffer composition was optimized to mimic physiolog-
ical conditions. We  found that the presence of detergent micelles
increased AP activity, presumably by reconstituting its native lipid
environment. It is noteworthy that screening the target in non-
physiological conditions could bias the hit identiﬁcation process
toward molecules that are inactive in physiological conditions.
Beside the optimal plate type and detergents illustrated in this
study, some assays may  require additional reagents in the reaction
buffer, such as carrier proteins, salts, or reducing agents, to ensure
sustained target stability.
Subsequent to the optimization of buffer constituents, the
kinetic parameters of AP were determined in order to estab-
lish the appropriate pH and substrate concentration for screening
of inhibitors. For each target class, the most adequate substrate
concentration for compound screening and potency assessment
depends on the kinetic parameters of the enzyme and the desired
modality of inhibition: concentrations below the KM favor the selec-
tion of inhibitors that are competitive for the substrate binding site
and disfavor the selection of un-competitive inhibitors, and vice
versa. If there is no preference for a particular type of inhibitor,
conducting the screen or dose–response studies at a substrate con-
centration around the KM is a good compromise. The kinetic studies
using AP demonstrated this enzyme performed well at neutral
etectio
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H as compared to alkaline pH. More importantly, these studies
llustrated the interconnection between pH optima and substrate
oncentration for AP and the need to optimize these two  param-
ters simultaneously. Kinetic studies also raised the necessity to
eplace the assay technology by a more sensitive one, which was
ompatible with the low substrate concentration and neutral pH
equirements of the assay.
While optimization of “one-factor-at-a-time” approach may
eem a priori a less cost-effective strategy for assay development
han optimizing “all-in-one-go” approach, the ﬁrst one is more
ractical to optimize independent assay variables whereas the
econd one is more powerful to co-optimize simultaneously var-
ous inter-dependent parameters. For example, the optimization
f plate type, pH, and substrate concentration could be a priori
stablished in parallel in an all-in-one experiment by titrating
imultaneously substrate and pH in different plate types. While
his approach would save time by reducing to one experiment
he optimization of three assay components, it would increase
eagent consumption and thus assay costs by increasing the num-
er of assay replicates in multiple plate types. In general, as the
umber of independent parameters to be optimized in a multi-
actorial assessment increases linearly, the number of conditions
o be tested and the consumption of reagents and consumable
row exponentially, making this approach expensive, impracti-
al and error prone, despite the potential time saving beneﬁts. In
ontrast, the optimization of parameters that are inter-dependent
hould be conducted solely by a designed all-in-one approach.
n this case, a one-factor-at-a-time strategy would identify local
nstead of global optima, thus leading to select potentially sub-
ptimal assay conditions. For example, the optimization of pH
nd substrate concentration (two inter-dependent assay param-
ters) was conducted by simultaneous titration of these two
ssay variables in a two-dimensional matrix design. This approach
llowed to identify not only local pH optima at ﬁxed substrate
oncentrations or vice versa, but global optima for these two  param-
ters. Therefore, optimizing a combination of one-factor-at-a-time
nd all-in-one designed experiments is recommended to success-
ully develop and optimize an in vitro assay for any target of
nterest.
Upon assay optimization, the suitability of the selected assay
onditions for compound screening was veriﬁed using reference
ompounds. Sodium orthovanadate inhibited the AP activity in a
ose dependent manner and kinetic studies sodium orthovana-
ate conﬁrmed the reversibility & mode of action of this inhibitor,
roviding further support to the appropriateness of the developed
ssay for mode of action studies. In general, assay conditions that
ave been optimized adequately should enable to determine the
echanism of action of inhibitors correctly.
However, caution must be taken while using the screening cam-
aign assay conditions to establish the inhibition modality and
inding afﬁnity of the diverse chemical series identiﬁed in the
creening campaign. In general, the ﬁrst step in the characterization
f the hits could be the reversibility assessment described in Section
.2.1 and depicted in Fig. 4B. The methodology described in Section
.2.2 can in-general be followed to determine compound potency
nd mechanism-of-action, and guide SAR optimization of reversible
nhibitors. However, for time-dependent (slow binding, slow dis-
ociation, and tight binding) and irreversible (covalent binding)
nhibitors, modiﬁcations to the assay methodology and analysis
re required in order to correctly establish compound potency
nd prioritize candidates. Although tight binding and irreversible
nhibition may  be a priori undesirable mechanisms for target atten-
ation due to long-term or permanent inactivation of the target
nzyme, in some instances molecules with these characteristics
ay  possess clinical advantages by providing high selectivity and
ustained pharmacological responses [11].
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The AP assay protocol was further miniaturized and automated
to reduce costs, increase throughput, and ensure day-to-day repro-
ducibility. The suitability of the assay for small molecule screening
and proﬁling was validated by quantitative assessment of the sig-
nal variability within plates, between plates, and between days, and
comparison of performance indicators with recommended cut-off
values for assay acceptance.
The overall scheme of assay development, validation, quantita-
tive assessment and screening paradigm described herein could be
used as a general guide of assay development for any mammalian
or microbial enzymatic target class. Besides the primary screening
described herein, it is desirable to counter-screen the hits against a
panel of structurally and functionally related enzyme classes. In the
case of mammalian targets, these secondary screenings serve the
purpose of determining compound selectivity and predict potential
off-target effects. In the case of microbial targets (bacterial, proto-
zoan, or fungal proteins), these assessments explore the potential
spectrum of the identiﬁed antimicrobial candidates. In both cases,
assay conditions for each secondary target in the selectivity panel
must individually be optimized following similar process described
for the primary target.
In conclusion, our study illustrates the comprehensive process
of developing and validating an enzymatic assay for discovery and
proﬁling of small molecule inhibitors. The most critical parameters
for assay development and validation, quantitative assessments,
bottlenecks, and the corrective measures to overcome them were
discussed in detail using AP as a model target.
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